Online inquiry

IVTScrip™ mRNA-Human ARHGEF33, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK25017MR)

This product GTTS-WK25017MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARHGEF33 protein. This product can be used in Oogenesis phase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001145451.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 100271715
UniProt ID A8MVX0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARHGEF33, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK25017MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK13974MR IVTScrip™ mRNA-Human ACTR3C, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACTR3C
GTTS-WK27711MR IVTScrip™ mRNA-Human ARHGEF18, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARHGEF18
GTTS-WK21540MR IVTScrip™ mRNA-Human ANKS6, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANKS6
GTTS-WK21605MR IVTScrip™ mRNA-Human Apelin, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Apelin
GTTS-WK26270MR IVTScrip™ mRNA-Human ARPC4-TTLL3, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARPC4-TTLL3
GTTS-WK26277MR IVTScrip™ mRNA-Human ARRDC1, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARRDC1
GTTS-WK13101MR IVTScrip™ mRNA-Human ADAMTS17, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADAMTS17
GTTS-WK10168MR IVTScrip™ mRNA-Human ADRB2, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADRB2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW